Good clinical response to imatinib mesylate in atypical thymic carcinoid With KIT overexpression.
Hamada
Satoshi
S
Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masago
Katsuhiro
K
Mio
Tadashi
T
Hirota
Seiichi
S
Mishima
Michiaki
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000096:biosynthesis*; D011743:Pyrimidines / Q000627:therapeutic use*; D013945:Thymoma / Q000188:drug therapy* / Q000201:enzymology*; D013953:Thymus Neoplasms / Q000188:drug therapy* / Q000201:enzymology*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit